AstraZeneca Vice President, Head of Breast Cancer Franchise, Discusses Impact of Truqap Approval

The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.

Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.

Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.

Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.

Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.

A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.

Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring remains a key consideration.

What North American and APAC sponsors need to know about EU Joint Clinical Assessment — and why EMA approval doesn't guarantee reimbursement.